Clinical Trials | A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

The University of Virginia seeks adults ages 18 and over with relapsed or refractory B-cell Non-Hodgkin Lymphoma for a research study. The purpose of the study is to evaluate if the investigational drug called loncastuximab tesirine in combination with another anti-cancer agent is a safe and effective treatment for relapsed or refractory B-cell Non-Hodgkin Lymphoma. If you are eligible to participate, you may receive loncastuximab tesirine and another anti-cancer agent (gemcitabine, lenalidomide, polatuzumab vedotin,) for up to one year, or potentially longer if you are clinically benefiting from it. The combination study drug will be administered as following in an arm and a dose level you will be assigned to one arm: Arm A: + Gemcitabine: intravenous infusion on Day 1 every 3 weeks Arm B: + Lenalidomide: orally once daily 2 weeks on and 1 week off Arm C: + Polatuzumab vedotin will be administered at 1.8mg/kg by intravenous infusion on Day 1 every 3 weeks Currently only Arm C is available for screening. After you stopping the study treatment, you will be continued to be contacted approximately every 12 weeks up to 2 years to keep track of how you are doing. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05118841 [email protected]